Organisation paid for research Program year 2025 Source: CMS Open Payments

Thomas Jefferson Univ

Neither a doctor nor a teaching hospital

Research payments

$3,125,283

2,268 payments

Through program year 2025, Thomas Jefferson Univ is reported as receiving $3,125,283 in research payments, across 2,268 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$148,707	31
2024	Research	$488,312	542
2023	Research	$497,040	314
2022	Research	$654,560	437
2021	Research	$420,690	716
2020	Research	$328,178	103
2019	Research	$587,795	125

Breakdown

Who paid Research payments · program years 2019–2025

Novo Nordisk AS $1,557,600 2,164 payments
AstraZeneca Pharmaceuticals LP $1,227,039 61 payments
GlaxoSmithKline, LLC. $139,225 8 payments
AstraZeneca UK Limited $135,771 3 payments
Janssen Research & Development, LLC $27,756 2 payments
Alexion Pharmaceuticals, Inc. $23,241 1 payment
Merck Sharp & Dohme Corporation $9,419 2 payments
AstraZeneca AB $1,825 1 payment
Boehringer Ingelheim Pharma GmbH & Co.KG $1,775 22 payments
Actelion Pharmaceuticals, Ltd $1,200 2 payments

Studies the money was for Research payments · program years 2019–2025

Nn9924-4558 $1,036,624 61 payments
Window of Opportunity for Durvalumab plus Metformin Trial of in Squamous Cell Carcinoma of the Head and Neck $622,797 5 payments
Ex9924-4473 $267,278 720 payments
A Pilot trial of Hyperthermia in combination with Olaparib in breast cancer patients with chest wall recurrences. $147,266 1 payment
A Phase 3, Randomized, Double-Blind, Multicenter Study of Dostarlimab $111,575 7 payments
ROSY-O Roll Over Study for Patients Who Have Completed a Previous Oncology Study with Olaparib and Are Judged by the Investigator to Clinically Benefit From Continued Treatment $79,946 2 payments
Nn9535-4321 $71,950 547 payments
Nn9535-4801 $71,910 490 payments
The CHRONICLE Study is a multi center,non interventional,prospective cohort study of adults with severe asthma who do not achieve control with high-dose ICS therapy with additional controllers and or require systemic corticosteroid or monoclonal antibod $69,405 2 payments
Nn9931-4553 $63,228 217 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.